- Earnings highlights
Net income: Loss of $12.9 million compared with a loss of $7.9 million a year ago.
Diluted earnings: Loss of 38 cents a share compared with a loss of 24 cents a year ago.
Average earnings forecast: Loss of 39 cents a share by one analyst surveyed by Zacks Investment Research.
Share price: Rose 14 cents to close at $4.81.
Source: Targacept Inc.
Posted: Tuesday, November 5, 2013 10:12 am
Higher research and development expenses contributed to a larger loss for Targacept Inc. in the third quarter, the Winston-Salem biotechnology company reported Tuesday.
Targacept develops drugs based on the use of nicotinic receptors to treat diseases, with a primary focus on the central nervous system. It has served as an anchor of the Triad’s biotechnology sector for several years.
Tuesday, November 5, 2013 10:12 am.